

ASX Announcement

HER-Vaxx Immunotherapy Patent Granted in South Korea

- South Korea patent granted in major HER-2 positive gastric cancer market
- Patent provides method of composition and method of use protection to 2036

Sydney, Australia, 6 January 2022: Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announced it has received a Notice of Grant from the South Korean Intellectual Property Office for Patent Application number 10-2017-7032987 which protects its HER-Vaxx immunotherapy, currently in development for HER-2 positive gastric cancer.

The patent titled “A VACCINE COMPOSITION AND USES THEREOF” protects the method of composition and method of use of Imugene’s HER-Vaxx immunotherapy to 2036.

Importantly, South Korea is a selected country to conduct the nextHERIZON Phase 2 clinical trial in 2022. This is an open-label, signal generating, phase 2 study of HER-Vaxx in combination with chemotherapy or pembrolizumab in patients with metastatic HER2/neu over-expressing gastric or gastroesophageal junction (GEJ) adenocarcinomas who have previously received trastuzumab and progressed on this treatment.

South Korea has one of the highest incidence rates of gastric cancer worldwide, with approximately one in five cases considered HER2 positive. Approximately 75% of all gastric cancer diagnoses are in Asia. Particularly high incidence rates in East Asia make South Korea a very large market for gastric cancer medications.¹

Imugene’s M.D. & CEO Ms Leslie Chong said: “Attaining the key South Korean patent, on top of gaining protection in Japan and China in 2021, is a very important milestone. This will protect HER-Vaxx in the world’s largest HER-2 positive gastric cancer markets until 2036.”

Imugene’s HER-Vaxx is a B-cell activating immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. The immunotherapy is constructed from several B cell epitopes derived from the extracellular domain of HER-2/neu. It has been shown in pre-clinical studies, in Phase I and now Phase 2 studies to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.

For more information please contact:

Leslie Chong

Managing Director and Chief Executive Officer

info@imugene.com

Investor Enquires

investor@imugene.com

Media Enquires

Matt Wright

matt@nwrcommunications.com.au

Follow us on Twitter @TeamImugene

Like us on Facebook @Imugene

Connect with us on LinkedIn @Imugene Limited

Reference:

¹ GLOBOCAN 2018 Graph production: IARC. World Health Organization. August 2020.

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer

Imugene Limited, Level 3, 62 Lygon Street, Carlton, VIC, 3053, Australia